-
Recent Posts
- December 01 2013 – Human stem cells converted to functional lung cells
- November 30 2013 – Keyhole lung transplant performed on 60-year-old in Chennai
- November 27 2013 – FibroGen Announces Observations of Possible Disease Stabilization and Improvement in Interim Analysis of Phase 2 Study of FG-3019
- November 15 2013 – Enzo Biochem Announces Study in Leading Scientific Journal Linking Idiopathic Pulmonary Fibrosis, a Deadly Human Disease with No Effective Treatment Options, to Presence of a Monkey Virus
- November 10 2013 – Research by Saint Louis University scientists offers way to disrupt fibrosis
Recent Comments
- Fish With Captain Frank on June 20 2012 MicroDose Therapeutx and Moerae Matrix Announce Collaboration to Develop Novel Inhaled Treatment for Idiopathic Pulmonary Fibrosis (IPF)
- Raymond on June 9 2011 – Ascend Trial – Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Johng182 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- Johnf73 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- extreme rush on June 28 2012 Grasping at Straws while Gasping for Air
Archives
Categories
Meta
Tag Archives: Esbriet
October 11 2013 – UAB gets $9.7 million to find treatments for deadly lung disease pulmonary fibrosis
UAB gets $9.7 million to find treatments for deadly lung disease pulmonary fibrosis by Bob Shepard Grant will allow UAB researchers to study novel therapies for pulmonary fibrosis, a deadly lung disease with no approved treatments. The University of Alabama at … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
October 10 2013 – Finding cellular causes of lung-hardening disease
Medical Xpress)—Idiopathic Pulmonary Fibrosis, or IPF, is an incurable lung disease that, over time, turns healthy lung tissue into inflexible scar tissue – hardening the lungs and eventually causing respiratory distress and death. Currently, there is no cure. Phil Sannes, … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, IPF, Lung Transplant, Medical, Medical News, NAC, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
October 9 2013- Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis
Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. Promedior is … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
1 Comment
October 3 2013 – Newly identified biomarkers help predict outcome in deadly lung disease
New Haven, Conn. – A Yale-led study has identified a gene expression profile that can predict outcomes and lead to better treatment for one of the most lethal lung diseases, idiopathic pulmonary fibrosis (IPF). The study appears in Science Translational … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
September 29 2013 – Trial to determine if stem cells can help with rare lung disease
By Cindy Krischer Goodman cindykgoodman@gmail.com Jose Guzman began gasping for breath while using his treadmill on the lowest setting and knew something was wrong. His search for answers led him to the diagnosis of a rare lung disease with no … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
September 28 2013 – Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
Abstract During the past decade important progress has been made regarding the pathogenesis of idiopathic pulmonary fibrosis (IPF), which is the most devastating form of idiopathic interstitial pneumonia with a median survival of 3 years. The knowledge gained has been … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, www.ipftoday.com
Leave a comment
September 2 2013 – New pathway to treat colorectal cancer, pulmonary fibrosis
Israel researchers uncover secrets of how a certain white blood cell can flip from being a ‘good guy’ to a ‘bad guy’ in diseases with no current cure. Doctoral student Danielle Karo-Atar studying macrophages at Tel Aviv University. A type … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
September 2 2013 – Boehringer Ingelheim to present highly anticipated data from landmark TIOSPIR™ trial, and their respiratory pipeline products in COPD, asthma, IPF and lung cancer at ERS 2013
INGELHEIM, Germany–(BUSINESS WIRE)– For media outside the UK, US and Canada Results of COPD Phase III landmark trial TIOSPIR™comparing safety and efficacy of SPIRIVA® Respimat® versus SPIRIVA® HandiHaler® Phase III trial results on investigational compound olodaterol* Respimat® as once-daily maintenance bronchodilator monotherapy in COPD … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
August 8 2013 – Aradigm Awarded NIH Grant to Investigate New Methods of Diagnoses of Aspirations of Gastrointestinal Contents into the Respiratory Tract with Scientists at UC San Francisco
HAYWARD, Calif.–(BUSINESS WIRE)– The National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), awarded Aradigm Corporation (ARDM) a Small Business Initiative Research (SBIR) grant to investigate the development and validation of tests for gastro-esophageal reflux with aspirations into … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
August 5 2013 – Oral N-acetylcysteine (NAC) reduces COPD exacerbations in RCT (Chest)
Oxidative stress (imbalance between oxidants and antioxidants) is part of the story of how COPD causes symptoms of cough and shortness of breath. Cigarette smoke is the main source of oxidation damage in the lungs leading to COPD, but even … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment